New drug combo aims to boost CAR-T success in hard-to-treat lymphoma

NCT ID NCT07341191

First seen Jan 16, 2026 · Last updated Jun 16, 2026 · Updated 25 times

Summary

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible for CAR-T therapy will take these drugs alongside their usual care. The goal is to see if this combination leads to better cancer control and longer survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BCCA - Vancouver

    NOT_YET_RECRUITING

    Vancouver, British Columbia, V5Z 4E6, Canada

    Contact Phone: •••-•••-••••

  • University Health Network

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact

Conditions

Explore the condition pages connected to this study.